Cardiovascular Drug Development: Protocol Design and Methodology - Rilegato

 
9780824719272: Cardiovascular Drug Development: Protocol Design and Methodology
Rilegato
ISBN 10: 0824719271 ISBN 13: 9780824719272
Casa editrice: CRC Press, 1998

Sinossi

These multidisciplinary presentations provide information essential to devising effective drug protocols in cardiovascular drug development, facilitating the approval process.
Guides researchers and developers through the government drug approval process, facilitating development, minimizing costs, and harmonizing international standards employed in the creation of vital new cardiovascular therapies!
Cardiovascular Drug Development

  • explores the delicate balance of efficacy and safety that cardiovascular therapy must achieve to gain regulatory approval
  • discusses the search for surrogates and the need in some areas for natural history endpoints
  • reviews optimum strategies for protocol design in the development of drugs to treat hypertension, cardiac arrhythmias, heart failure, coronary artery disease, and hypercholesterolemia and other lipid disorders
  • compares and contrasts the varying standards of evidence for drug approval in the United States, Europe, and Asia
  • and more!
    Cardiovascular Drug Development will prove to be a valuable asset for cardiologists, pharmacologists and pharmacists, regulatory affairs specialists, and directors of research and development for pharmaceutical companies.

    • Le informazioni nella sezione "Riassunto" possono far riferimento a edizioni diverse di questo titolo.

    Contenuti

    Drug Discovery and Development, John C. Somberg

    Development of Congestive Heart Failure Therapy

    Background Therapy in Congestive Heart Failure Studies, Jeffrey S. Borer
    Congestive Heart Failure Trial Design, Raymond John Lipicky
    Angiotensin-Converting Enzyme Inhibitors for Mortality Reduction in Congestive Heart Failure: Should Approval Be Granted for a Class Effect?, Jeffrey S. Borer and John C. Somberg
    Sudden Death in Congestive Heart Failure Trials, John C. Somberg
    Panel Discussion, Jeffrey S. Borer, Moderator

    Development of Antihypertensive Therapy

    Antihypertensive Clinical Trials, Raymond John Lipicky
    Calcium Channel Blockers: Safety Issues, Jeffrey S. Borer
    Panel Discussion, Jeffrey S. Borer, Moderator

    Development of Antiarrhythmic Drug Therapy

    Antiarrhythmics: Indications, Claims, and Trial Design, Raymond John Lipicky
    Supraventricular Tachycardia Drugs and Trial Design Issues, Robert Fenichel
    Antiarrhythmic Trials: Update, John C. Somberg
    Inter-Ethnic Differences in the Susceptibility to Drug-Induced QT Interval Prolongation and Torsade de Pointes, Satish Singh
    Panel Discussion, John C. Somberg, Moderator

    Development of Antilipid and Anti-Ischemic Therapy

    Antilipid Trial Endpoints, David Orloff
    Natural History Endpoints and Angina Trials, Raymond John Lipicky
    Development of Antiplatelet Drugs, Stephen Fredd
    Panel Discussion, Jeffrey S. Borer, Moderator

    Conclusion

    Future Directions of Cardiovascular Drug Development, Jeffrey S. Borer

    Product Description

    Book by None

    Le informazioni nella sezione "Su questo libro" possono far riferimento a edizioni diverse di questo titolo.

    Editore
    CRC Press
    Data di pubblicazione
    1998
    Lingua
    Inglese
    ISBN 10 
    0824719271
    ISBN 13 
    9780824719272
    Rilegatura
    Copertina rigida
    Numero edizione
    1
    Numero di pagine
    248
    Redattore
    Somberg John
    Contatto del produttore
    non disponibile
    Persona responsabile
    non disponibile